This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Food and Drug Administration (FDA) announced on May 1 that the Apple Atrial Fibrillation (AFib) History Feature now qualifies as a Medical Device Development Tool (MDDT) to assess AFib burden estimates within clinical studies.
Atrial fibrillation catheter ablation (AFCA) improved clinical outcomes compared with medical treatment alone, and early AFCA was associated with better outcomes than late AFCA, particularly decreased risk of heart failure (HF) hospitalization and atrial fibrillation (AFib) recurrence.
he utility of left atrial appendage occlusion (LAAO) as a therapy for stroke prevention in patients with nonvalvular atrial fibrillation (AFib) is the focus of a State-of-the-Art Review published Jan. 8 in JACC: Clinical Electrophysiology.
Not only do former smokers have lower risk of atrial fibrillation (AFib) than current smokers, but patients who quit smoking may reduce their AFib risk while doing so, according to a longitudinal cohort study utilizing UK Biobank data, published Sept. 11 in JACC: Clinical Electrophysiology.
Bleeding events in anticoagulated patients with atrial fibrillation (AFib) was strongly associated with a new cancer diagnosis, highlighting the importance of timely investigation of bleeding, according to a study published Feb.
In this podcast hosts highlight the 2023 Guideline updates and the importance of a patient centered cardiac care team approach to AFib diagnosis, management, and treatment.
History of prior heart failure (HF) was found to influence prognostic implications of atrial fibrillation (AFib) in patients hospitalized for HF, with permutations of prior HF, prior AFib and AFib as presenting rhythm differentiating outcome.
Although atrial fibrillation/atrial flutter (AFib/AFL) are common manifestations of transthyretin amyloid cardiomyopathy (ATTR-CM), a post hoc analysis of the ATTR-ACT study, published April 30 in JACC: CardioOncology, found they do not predict all-cause mortality.
Rivaroxaban did not reduce the incidence of cognitive decline, stroke or transient ischemic attack (TIA) in patients younger than 65 with nonvalvular atrial fibrillation (AFib) and low risk for stroke, according to results from the BRAIN-AF trial.
Pulsed field ablation (PFA) was shown to be effective in treating patients with paroxysmal atrial fibrillation (AFib), with more patients free from atrial arrhythmias (AA) when compared with patients treated with thermal ablation, according to results from a secondary analysis of the ADVENT trial.
Women who develop hypertensive disorders of pregnancy (HDOP) in their first delivery have a significantly increased cause-specific hazard ratio (csHR) of incident atrial fibrillation (AFib) compared with women who do not, according to a study published Feb.
The newest clinical guideline released by the ACC and the American Heart Association (AHA) provides new and updated recommendations for preventing and optimally managing atrial fibrillation (AFib).
Higher hospital and physician atrial fibrillation (AFib) ablation procedure volumes were associated with increased acute procedural success and lower rates of major adverse events (MAEs), according to a study published in Heart Rhythm.
Edoxaban was comparable to warfarin in preventing stroke or systemic embolism and intracardiac thrombus in patients with non-valvular atrial fibrillation (AFib) within three months after bioprosthetic valve surgery, based on preliminary findings from the ENBALV trial presented at AHA 2024.
Left atrial appendage closure (LAAC) in patients at moderate to high risk for stroke who were undergoing catheter atrial fibrillation (AFib) ablation resulted in significantly less bleeding compared with oral anticoagulation, based on findings from the OPTION trial presented at AHA 2024 and simultaneously published in NEJM.
This does NOT seem irregularly irregular enough for AFib … Instead — there is almost “group beating” with “Wenckebach periodicity”. Here the full text of the article: Accelerated Idioventricular Rhythm: History and Chronology of the Main Discoveries
Device-recognized atrial fibrillation (AFib) may be associated with a higher risk of all-cause mortality in patients with cardiac implantable electronic devices (CIEDs), according to a study published in Circulation.
In patients with high-risk atrial fibrillation (AFib) and stable coronary artery disease, endoxaban monotherapy when given as a long-term antithrombotic therapy was associated with better net clinical benefit than edoxaban plus a single antiplatelet agent, based on findings from the EPIC-CAD trial presented at ESC Congress 2024 in London and simultaneously (..)
Village doctors in rural China trained to manage the care of older adults with atrial fibrillation (AFib) and supported by AFib experts in tertiary hospitals through telemedicine lowered the risk of AFib-related adverse cardiovascular events by 36% over three years, based on findings from the MIRACLE-AF trial presented at ESC Congress 2024 in London. (..)
In this installment of Atrial Fibrillation (AFib) and Antiarrhythmic Drugs (AADs) series, Dr. Suneet Mittal interviews Dr. Jeff Healey about evidence supporting the guidelines and how they compare to previous guidelines.
Asundexian was associated with a higher incidence of stroke or systemic embolism, but less major bleeding, compared with apixaban among patients with atrial fibrillation (AFib) who were at high risk for stroke, based on findings from the OCEANIC-AF trial presented at ESC Congress 2024 in London and simultaneously published in The New England Journal (..)
KEY Point: Nothing other than AFib with WPW results in a ventricular response this fast ( which is why Figure-2 is pathognomonic for AFib in a patient with WPW ). Regarding AFib with WPW: The very rapid heart rate and at times extremely short R-R intervals put the patient with AFib and WPW at risk of cardiac arrest from VFib.
A short educational program for targeted at health care professionals in France, Germany, Italy, Poland, Spain and the UK increased patient-level adherence to guideline recommendations on atrial fibrillation (AFib) management, based on findings from the STEEER-AF trial presented at ESC Congress 2024 in London.
Performing additional catheter ablations targeting diseased myocardium along with the standard approach of pulmonary vein isolation (PVI) to treat persistent atrial fibrillation (AFib) did not reduce the recurrence of AFib at one year, based on findings from the SUPPRESS-AF trial presented at ESC Congress 2024 in London.
The ACC and the American Heart Association (AHA) guideline for the management of atrial fibrillation (AFib) provides a comprehensive multi-society update, the first in a decade, and offers a new staging system for AFib, upgrades recommendations for catheter ablation, rhythm control and left atrial appendage occlusion (LAAO), and emphasizes the importance (..)
One of my New Year's resolutions was to read the entire 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation (AFib).
One-time screening for atrial fibrillation (AFib) using a 14-day, electrocardiographic (ECG) patch monitor in individuals aged ≥70 years did not reduce rates of bleeding or stroke, based on results from the GUARD-AF trial.
Compared with a sham procedure, pulmonary vein isolation resulted in a statistically significant and clinically important decrease in atrial fibrillation (AFib) burden at six months, according to results from the SHAM-PVI trial presented at ESC Congress 2024 in London and simultaneously published in JAMA.
Relaxed control of potassium levels and only giving supplements in the rare event that levels became pathologically low was just as effective in preventing atrial fibrillation (AFib) after cardiac surgery as tightly controlling levels, according to findings from the TIGHT-K study.
The April 6, 2023 post — excessive baseline artifact misdiagnosed as AFib ( instead of sinus rhythm with AV Wenckebach — as in Figure-4 in this post ). The September 27, 2019 post — for the Rowlands & Moore article with the above-noted formulas for recognizing the “culprit” extremity. The September 15, 2023 post — for PTA.
A novel causal machine learning algorithm can determine which patients with atrial fibrillation (AFib) are more likely to benefit from left atrial appendage occlusion (LAAO) compared with direct-acting oral anticoagulant (DOAC) therapy, according to a study published Feb.
In this weeks View, Dr. Eagle looks at arrhythmia recurrence and rhythm control after catheter ablation for atrial fibrillation. He then discusses long-term outcomes in transthyretin amyloid cardiomyopathy in patients treated with tafamidis.
Additional rhythm-control strategies are frequently continued after index ablation for atrial fibrillation (AFib), according to a study published Feb. 12 in JACC: Clinical Electrophysiology.
Special Edition: PharmD Appreciation: “PulseCheck†is a series within CardiaCast that is designed for Cardiovascular (CV) Team members who are new, or new to cardiology, offering practical team-based solutions to the everyday challenges.
Ibutilide can convert atrial fib, or if the atrial fib is resistant to electrical cardioversion, ibutilide can facilitate electrical cardioversion (see my description of the New England Journal article below). I focus my comment on a few additional aspects regarding new AFib. Here is the ECG after ibutilide: What do you notice?
In this interview, Drs. Steven Nissen and Benjamin O’Brien discuss the TIGHT K trial results which proved that practitioners can safely cease the widespread practice of maintaining high-normal potassium levels after isolated coronary artery bypass grafting surgery.
In this weeks View, Dr. Eagle looks at left atrial appendage occlusion for stroke prevention in patients with AFib. He then discusses a new treatment for severe hypertrophic cardiomyopathy in children. Finally, Dr. Eagle explores anticoagulation for patients who are hospitalized with COVID-19.
Food and Drug Administration (FDA) has approved the FARAPULSE Pulsed Field Ablation System for isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic, paroxysmal atrial fibrillation (AFib), according to a Boston Scientific press release.
In this week’s View, Dr. Eagle looks at anticoagulation for post-operative atrial fibrillation after isolated coronary artery bypass grafting. He then examines a meta-analysis of invasive vs. conservative management of non-ST-elevation acute coronary syndromes with previous coronary artery bypass grafting.
In this week’s View, Dr. Eagle looks at transcatheter-based intervention for tetraology of Fallot. He then examines how a small left ventricle in patients with atrial fibrillation is associated with increased cardiovascular risk.
Marine and Pathak break down the key clinical takeaways and valuable insights on optimizing AFib management and improving outcomes through evidence-based strategies.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content